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1 INTRODUCTION 
1.1 Interstitial lung disease 
Interstitial lung disease (ILD) is a collective term for various lung conditions which are 
characterized by thickening of the alveolar walls by inflammation or fibrosis. ILD can be 
caused by exposure to noxious substances as organic antigens, air pollutants, or drugs, but can 
also occur as result of systemic or autoimmune disease where multiple organs, not only the 
lung, are damaged. Prolonged ILD often leads to interstitial scarring, i.e. lung fibrosis.  
Hypersensitivity pneumonitis (HP), for example, also referred to as extrinsic allergic alveolitis 
(EAA), is typically caused by repeated inhalation of agricultural dusts (Selman et al., 2012). 
If HP is diagnosed at an early stage and the responsible harmful compound identified, then 
avoiding exposure usually results in attenuation or even reversion of disease (Fernandez Perez 
et al., 2013). However, chronic exposure can lead to severe impairment of lung function and 
distortion of lung structure so that ultimately transplantation may be the only effective 
therapeutic option (Selman et al., 2012, Grunes et al., 2013). Another prominent cause of ILD 
is medication. Numerous drugs have been associated with ILD as adverse side effect 
including anti-inflammatory, antimicrobial, cardiovascular, and cytotoxic drugs 
(Schwaiblmair et al., 2012). Also in these cases, early diagnosis and discontinuation of the 
drug usually lead to improvement of lung fibrosis and even full recovery is possible. 
However, if the diagnosis is performed at a later stage with a significant degree of established 
lung fibrosis, mortality rates can be as high as 40% (Schwaiblmair et al., 2012). Similarly, 
systemic disease can result in interstitial lung fibrosis: Sarcoidosis, for instance, is a systemic 
primarily inflammatory disease with unknown cause which can involve multiple organs, but 
mostly affects the lung. Here, nodules of inflamed tissue, so-called granulomas, form which 
may resolve without irreversible damage (Valeyre et al., 2014), but which, in 20–25% of the 
patients, result in pulmonary fibrosis and permanent lung dysfunction (Patterson et al., 2013). 
Classical autoimmune diseases, e.g. scleroderma, rheumatoid arthritis, and systemic lupus 
erythematosus, also often manifest in fibrosis of the lung and other organs and pulmonary 
involvement has a major impact on morbidity and mortality of patients (Kronbichler et al., 
2013, Vij et al., 2013).  
Idiopathic pulmonary fibrosis (IPF) is the most fatal ILD with a five-year survival rate of 30-
50% and few treatment options (Kim et al., 2006). Two recently FDA-approved drugs for IPF 
therapy, pirfenidone and nintedanib, decelerate but do not stop disease progression in IPF 
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patients by decreasing lung function decline. They also show considerable side effects and 
their mechanisms of action are incompletely understood (King et al., 2014, Richeldi et al., 
2014). Hence, considering the prognosis of IPF and other forms of pulmonary fibrosis at 
advanced stage, there is a clear need to identify novel drug targets for late-stage ILD, in 
particular for IPF. 
1.2 IPF pathogenesis 
The etiology of IPF is poorly understood. The current belief is that an aberrant wound-healing 
response is initialized by repeated micro-injuries to the lung epithelium. This leads to 
secretion of fibrotic mediators including transforming growth factor β (TGF-β) which results 
in an accumulation of (myo-)fibroblasts in the alveolar region (Selman et al., 2001, Blackwell 
et al., 2014, Renzoni et al., 2014, Selman et al., 2014, Wolters et al., 2014). The latter 
overgrow the delicate alveolar lung tissue and secrete increased amounts of extracellular 
matrix (ECM) proteins.  
1.2.1 The airway epithelium 
Traditionally, research on IPF pathogenesis has focused on alveolar epithelial-mesenchymal 
cross-talk as disease-initiating mechanism and fibroblast foci as final manifestation of disease 
(Selman et al., 2001, Renzoni et al., 2014, Wolters et al., 2014). Alveolar epithelial cells have 
been shown to activate TGF-β from latent complexes in the ECM (Tatler et al., 2012, 
Henderson et al., 2013, Sheppard, 2015), release TGF-β-containing exosomes (Borges et al., 
2013), secrete connective tissue growth factor (CTGF) and sonic hedgehog (SHH), and 
release Wnt1-inducible signaling protein (WISP1) (Konigshoff et al., 2009), all contributing 
to activation of (myo-)fibroblasts. Importantly, the discovery that a MUC5B promoter 
polymorphism was associated with increased risk of developing familial and sporadic IPF 
strongly suggested a causal involvement also of the bronchial or the distal bronchiolized 
epithelium (Seibold et al., 2011, Hunninghake et al., 2013, Seibold et al., 2013). This 
prompted a number of studies aiming to describe the cellular composition of the bronchial 
epithelium and proliferative bronchiolar lesions which are characteristic for IPF and include 
hyperplasia and metaplasia of bronchiolar and bronchiolo-alveolar junctions, 
bronchiolization, and honeycombing (Plantier et al., 2011, Seibold et al., 2013, Smirnova et 
al., 2016). Still, the role of these structures in IPF pathogenesis remains elusive. 
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1.2.2 Excessive production of extracellular matrix by the interstitial (myo)fibroblast  
Multiple progenitor cells may contribute to the myofibroblast population, but the most well-
established source is the interstitial fibroblast (Rock et al., 2011). Myofibroblasts synthesize 
and deposit excessive amounts of extracellular matrix (ECM) proteins, like collagen type I, 
III, V, and fibronectin (Fernandez et al., 2012). The resulting accumulation of ECM in the 
alveolar region is the ultimate pathological feature of lung fibrosis, leading to progressive 
lung function decline (Selman et al., 2001, Wolters et al., 2014). Notably, recent studies 
highlight that collagens are the main components of the ECM including newly synthesized 
ECM in a fibrotic response (Decaris et al., 2014, Beachley et al., 2015). 
 
 
Figure 1: Excessive deposition of extracellular matrix (ECM) in the alveolar region and increased 
oxidative stress are two central pathological features in pulmonary fibrosis. Exogenous and endogenous 
sources cause increase of reactive oxygen species (e.g. hydrogen peroxide, H2O2, and superoxide anion, O2
-
)  and 
lead to depletion of glutathione (GSH). In response, the alveolar basement membrane as well as the interstitial 
extracellular matrix (ECM) can be modified and damaged, e.g. resulting in increased shedding () of ECM 
components. Little is known about the localization of potentially protective antioxidant proteins in the 
extracellular space.  
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1.2.3 Oxidative stress in interstitial lung disease and effects on the extracellular matrix 
Several lines of evidence support the involvement of oxidative stress in fibrotic lung disease 
(Liu et al., 2010, Cheresh et al., 2013). For instance, markers of increased oxidative stress 
have been detected in exhaled air and bronchoalveolar lavage fluid (BALF) of patients 
suffering from IPF, sarcoidosis and HP (Maier et al., 1991, Rahman et al., 1999, Rottoli et al., 
2005, Psathakis et al., 2006, Bargagli et al., 2007). Furthermore, depletion of glutathione, the 
most abundant low-molecular-weight antioxidant, has been reported in the epithelial lining 
fluid (ELF) of IPF, sarcoidosis, and HP patients (Cantin et al., 1989, Meyer et al., 1994, Behr 
et al., 2000, Boots et al., 2009). Finally, numerous endogenous and exogenous agents 
implicated in the aetiology of pulmonary fibrosis cause levels of reactive oxygen species 
(ROS) to increase. Extrinsic sources include cigarette smoke, asbestos, silica, and bleomycin, 
all well-known risk factors for pulmonary fibrosis. Endogenous ROS sources include 
superoxide and hydrogen peroxide-producing phagocytic cells, but also intra- and 
extracellular enzymatic systems which produce ROS, as e.g. members of the NADPH oxidase 
(NOX) family, the mitochondrial electron transport chain, or extracellular lysyl oxidase 
activity in collagen crosslinking (Kagan et al., 2003, Winterbourn, 2008, Hecker et al., 2009, 
Carnesecchi et al., 2011, cf. Figure 1). 
Importantly, the composition of the ECM is affected by oxidative stress (Kliment et al., 
2010). Several in vivo studies in mouse models of lung fibrosis have shown that ECM 
components as e.g. collagen, heparan sulphate, syndecan, and hyaluronic acid are increasingly 
fragmented or shed from the cell surface in response to oxidative stress (Fattman et al., 2003, 
Kliment et al., 2008, Kliment et al., 2009, Zelko et al., 2010). In line with these observations, 
increased levels of collagen III, hyaluronic acid, and syndecan-1 have also been reported in 
BALF from IPF and HP patients (Bjermer et al., 1989, Cormier et al., 1993, Kliment et al., 
2009, Kliment et al., 2010). A number of extracellular antioxidant proteins have been 
described to localize to the ECM of the lung, suggesting a potential protective role in presence 
of oxidative stress (Kinnula, 2005), in particular, glutathione peroxidase 3 (GPX3) and 
extracellular superoxide dismutase (EC-SOD or SOD3) (Kliment et al., 2008, Kliment et al., 
2009, Zelko et al., 2010, Burk et al., 2011, Yamada et al., 2012). While the role of EC-SOD 
in pulmonary fibrosis has received considerable attention (Gao et al., 2008), the regulation 
and distribution of GPX3 in this context had not been studied in detail. 
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1.3 Collagen biosynthesis and maturation  
Collagen biosynthesis is a highly complex process starting with transcription of collagen 
genes followed by translation and translocation of the nascent polypeptide chain to the rER, 
cotranslational modification and folding, trafficking across the Golgi network, secretion, and 
finally, extracellular processing and maturation (Ishikawa et al., 2015, cf. Figure 2). 
Folding in the rER requires several enzymes and molecular chaperones essential for post-
translational modifications (PTMs) and the folding of procollagen chains into triple helices, 
where one of the rate-limiting steps is the cis-trans isomerization of proline residues catalyzed 
by rER resident peptidyl prolyl isomerases (PPIases, Ishikawa et al., 2013). Two ER proteins 
participating in this multistep process are the collagen chaperones FK506-binding protein 10 
(FKBP10, see 1.3.2) and heat-shock protein 47 (HSP47, also called SerpinH1, Ishikawa et al., 
2015). PTMs like hydroxylation of lysyl or prolyl residues (cf. Figure 3), or glycosylation of 
hydroxylysines are essential for proper stability, assembly and secretion of procollagen, as 
well as for the final supramolecular structure of these molecules (Hudson et al., 2013). For 
instance, hydroxylation of proline residues in position 4 (4-hydroxyproline, cf. Figure 3) is 
known to increase thermodynamic stability of the triple helix (Ishikawa et al., 2013). Also, 
the degree of lysine hydroxylation in the collagenous and telopeptide regions of fibrillar 
collagens defines the extent, type, and stability of extracellular intermolecular collagen 
crosslinks (Eyre et al., 2008). At the same time, the functions of the comparatively rare 
prolyl-3-hydroxylation (3-hydroxyproline, cf. Figure 3) and O-glycosylations are far less 
understood.  
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Figure 2: Intracellular collagen biosynthesis and extracellular maturation of collagen I. 1) Cotranslational 
prolyl-4- and lysyl-hydroxylation of the nascent collagen polypeptide chain in the rough endoplasmic reticulum 
(rER) is followed by 2) glycosylation and prolyl-3-hydroxylation and 3) folding of the C- and N-terminal 
propeptides. 4) For collagen I, two properly folded α1 chain C-propeptides assemble with one α2 chain C-
propeptide, forming the triple helix nucleus. 5) Triple helix formation occurs in a zipper-like fashion and is 
dependent on peptidyl-prolyl isomerases and collagen chaperones, including FKBP10. 6) After packaging into 
COPII vesicles, collagen triple helices are transported via the trans-Golgi network and finally secreted into the 
extracellular space. 7) In the extracellular space, propeptide cleavage involving at least three proteases triggers 8) 
auto-assembly of collagen fibrils, an entropy-driven process. 9) Finally, fibrils are stabilized by crosslinking.      
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Figure 3: Examples for 
collagen post-translational 
modifications. Structures of 
(a) 3-hydroxyproline, (b) 4-
hydroxyproline, (c) 5-hydro-
xylysine, (d) the divalent 
collagen crosslink hydroxyl-
lysinoketonorleucine, and (e) 
the trivalent collagen crosslink 
lysyl pyridinoline. 
Following trans-Golgi trafficking and secretion, collagen is secreted into the extracellular 
space where spontaneous fibril assembly and collagen crosslinking mediated by enzymes of 
the lysyl oxidase (LOX) family occurs. 
1.3.1 Collagen biosynthesis and maturation in idiopathic pulmonary fibrosis 
It is incompletely understood how collagen biosynthesis and modification are altered in 
fibrosis and how such changes might affect extracellular collagen PTMs, adherent cell 
function, and disease progression. The concept of targeting extracellular collagen crosslinking 
as an anti-fibrotic strategy has received considerable attention in the past years, fueled by the 
discovery of the collagen crosslinking enzyme lysyl oxidase-like 2 (LOXL2) as a potential 
drug target for pulmonary fibrosis (Barry-Hamilton et al., 2010). However, a phase II study 
with a monoclonal anti-LOXL2 antibody has been terminated due to lack of efficacy 
(http://www.gilead.com/news/press-releases/2016/1/gilead-terminates-phase-2-study-of-
simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis). One must bear in mind that 
lysyl oxidases perform the final step of collagen maturation, acting on extracellular fibrillar 
collagen (Robins, 2007). Fibrillar collagen is resistant to most extracellular proteases (Manka 
et al., 2012, Panwar et al., 2013), suggesting that inhibition of LOXL2, acting after 
spontaneous fibril formation (Chen et al., 2009, Steplewski et al., 2012), might have limited 
effects on the reduction and resolution of collagen-rich fibrotic areas. Therefore, it is 
conceivable that collagen synthesis and processing must be inhibited at an earlier step. 
1.3.2 FK506-binding protein 10 (FKBP10) 
The family of FK506-binding proteins (FKBPs) belongs to the class of immunophilins, 
peptidyl-prolyl cis/trans isomerases (PPIases) with the ability to bind immunosuppressive 
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drugs. FKBPs bind FK506 (tacrolimus) and rapamycin via their FK506-binding domains 
(FKBD), which also exhibit the PPIase activity of the protein. Binding of FK506 or 
rapamycin typically results in inhibition of the PPIase activity. The nomenclature for the 
FKBPs is ambiguous as their gene names do not match with their traditional protein names, 
which reflect the molecular weight. Here, the gene name FKBP10 will be used consistently 
also for the protein (as recommended by the protein database Uniprot, 
http://www.uniprot.org/), even if in the literature FKBP65 is used as protein name to a large 
extent.  
FKBP10 contains four FKBDs, but only one FKBD can be inhibited by FK506 and 
surprisingly also by cyclosporine A, which is not known to inhibit PPIase activity in any other 
FKBP (Coss et al., 1995, Zeng et al., 1998). The current literature supports a major function 
of FKBP10 in folding and post-translational modification of collagen I. Mutations in the 
FKBP10 gene have been associated with recessive type XI of osteogenesis imperfecta and 
Bruck´s syndrome, collagen-related disorders characterized by growth deficiency, bone 
fragility and deformity (Alanay et al., 2010, Barnes et al., 2012). In OI patients with FKBP10 
deficiency, extracellular collagen crosslinking is dramatically reduced, caused by absent 
hydroxylation of the collagen telopeptide lysine. FKBP10 has therefore been suggested to be 
essential for lysyl hydroxylase activity (Barnes et al., 2012). Supporting this idea, two recent 
studies have independently provided evidence that FKBP10 modulates collagen lysyl 
hydroxylase 2 activity. Therefore, FKBP10 indirectly affects the generation of collagen 
hydroxylysines and thus the extent and stability of the extracellular collagen crosslinks 
introduced by enzymes of the lysyl oxidase (LOX) family (Gjaltema et al., 2016, Duran et al., 
2017).  
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2 AIMS OF HABILITATION 
Currently approved options for treatment of IPF, i.e. nintedanib and pirfenidone, merely 
decelerate lung function decline in patients and do not stop progression of disease, let alone 
reverse fibrosis. The overall aim of this thesis is therefore to identify novel therapeutic 
strategies for IPF, with a focus on modulating properties of the extracellular matrix, most 
importantly collagen.  
 
More specifically, the aims of this habilitation project were the following: 
 Investigate association of antioxidant proteins with the extracellular matrix in ILD 
 Investigate expression and function of FKBP10 in pulmonary fibrosis 
 Establish human-derived in vitro culture models for lung fibrosis for functional analysis 
 Elucidate the effects of current IPF therapeutics on collagen biosynthesis and fibril 
formation 
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3 MATERIAL AND METHODS 
3.1 Patient samples 
Resected human lung tissue and lung explant material for analysis and isolation of primary 
human cells was obtained from the BioArchive CPC-M for lung diseases at the 
Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München, Munich, Germany 
(Papers I-IV). All participants have given written informed consent and the study was 
approved by the local ethics committee of Ludwig-Maximilians University of Munich, 
Germany (333-10). For Paper I, additional patients were enrolled at the Thomayer Hospital, 
Prague, Czech republic. This study was approved by the Ethics Committee of Thomayer 
Hospital and the Institute of Clinical and Experimental Medicine, Prague, Czech Republic.  
All procedures were carried out in accordance with the approved guidelines.  
3.2 The mouse model of bleomycin-induced lung fibrosis 
The model of bleomycin-induced lung fibrosis is the best-established and most widely used 
mouse model for lung fibrosis (Moeller et al., 2008, Peng et al., 2013). Intratracheal 
instillation of bleomycin into mice leads to an initial acute lung injury, followed by an 
inflammatory response and lung fibrosis, which in our hands peaks at day 14 post-instillation 
and resolves over the next four weeks (Schiller et al., 2015, Staab-Weijnitz et al., 2015, 
Fernandez et al., 2016). Typical read-outs include lung function (flexiVent, SCIREQ), fibrotic 
markers on transcript and protein level (e.g. hydroxyproline content, collagen 1A1 
biosynthesis, collagen deposition, fibronectin, α-smooth muscle actin), histology (Masson 
Trichrome, immunofluorescence), and analysis of bronchoalveolar lavage (BAL). All animal 
experiments were conducted under strict governmental and international guidelines. 
3.3 Primary human lung fibroblasts as an in vitro model for fibrosis 
For expansion, primary human lung fibroblasts (phLF) from different donors are cultured in 
DMEM/F12 (Life Technologies) supplemented with 20% FBS (Pan Biotech) and 
penicillin/streptomycin. To mimic fibrotic conditions and allow for efficient biosynthesis of 
collagen, phLF are treated with transforming growth factor β1 (TGF-β1) and cultured in 
presence of 2-phospho-L-ascorbic acid. Typical readouts used in this work are collagen 
biosynthesis on transcript and protein level, collagen secretion, collagen post-translational 
modifications, and expression of proteins of the ER-resident collagen biosynthesis machinery.   
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3.4 Primary human bronchial epithelial cells  
Isolation, culture and differentiation of primary human bronchial epithelial cells (phBECs) 
from explants in our lab is established according to a published protocol (Fulcher et al., 2005, 
Schamberger et al., 2014). While submerged serum-free culture of these cells at low passages 
preserves basal cell-like properties, lifting cells to an air-liquid interface allows for 
organotypic culture of a pseudostratified epithelium composed of all epithelial cell types of a 
typical bronchial epithelium including basal cells, ciliated cells, Goblet cells, and Clara cells.  
3.5 Precision-cut lung slices 
Human precision-cut lung slices (PCLS) from lung resections or explants are being 
increasingly used as ex vivo models for chronic lung disease (Lauenstein et al., 2014, Uhl et 
al., 2015, Mercer et al., 2016). To prepare PCLS at our institute, a cannula is inserted into a 
visible airway and the lung segments are filled with warm agarose (3 %). Lung segments are 
cooled on ice to allow solidification of the agarose and then cut into 500 µm thick sections 
with a vibratome (Hyrax V55; Zeiss, Jena, Germany). The resulting PCLS are cultivated in 
culture medium, where they float on the surface and are viable for up to 5 days (Uhl et al., 
2015). Importantly, PCLS preserve much of the cellular composition of normal tissue, in 
contrast to de- and recellularized tissue scaffolds, which are also being explored as alternative 
model systems in the lung field (Parker et al., 2014, Wagner et al., 2014).  
3.6 Quantitative label-free mass spectrometry and solubility profiling 
The proteome analysis pipeline including quantitative detergent solubility profiling (QDSP) 
has been established by Schiller et al. (2015). For proteome analysis of murine and human 
tissue samples, typically ~100mg of fresh frozen lung tissue (wet weight) is homogenized in 
phosphate-buffered saline, followed by centrifugation and collection of the soluble proteins. 
For extraction of proteins from the insoluble pellet, the pellet is sequentially incubated with 
buffers of increasing sodium deoxycholate and sodium dodecylsulphate concentrations, i.e. 
increasing solubilization stringency, resulting in three protein fractions which are highly 
enriched for matrisome-associated and ECM proteins (Naba et al., 2012, Schiller et al., 2015). 
Protein fractions are digested using a combination of LysC protease and trypsin and the 
resulting peptides subjected to analysis by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) using a Quadrupole/Orbitrap type mass spectrometer (Q-Exactive, Thermo 
Scientific). MS raw files are analyzed with the MaxQuant software (Cox et al., 2008) and the 
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Andromeda search engine is used to match results with the Uniprot FASTA database (Cox et 
al., 2011). 
3.7 Other methods 
For detailed description of more conventional methods for quantification of gene expression, 
imaging, and functional analysis, I would like to refer to the attached original papers and 
manuscripts and references therein. 
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4 RESULTS AND DISCUSSION 
4.1 Glutathione peroxidase 3 associates with collagen in the extracellular 
matrix in interstitial lung disease (Paper I) (Schamberger et al., 2016) 
Aberrant antioxidant activity and excessive deposition of extracellular matrix (ECM), in 
particular collagens, are hallmarks of interstitial lung diseases (ILD). It is known that 
oxidative stress alters the ECM, but extracellular antioxidant defence mechanisms in ILD are 
incompletely understood. We therefore hypothesized that in ILD, lung cells secrete 
extracellular antioxidant proteins which associate with the ECM, in particular with collagen, 
and potentially protect the ECM from oxidative damage. 
Therefore, we initially extracted abundance and detergent solubility of known extracellular 
antioxidant enzymes from a proteomic dataset of bleomycin-induced lung fibrosis in mice 
(Schiller et al., 2015). We found that superoxide dismutase 3 (Sod3), Gpx3, and selenium-
dependent Gpx activity were increased in mouse BALF during bleomycin-induced lung 
fibrosis. In lung tissue homogenates, Gpx3, but not Sod3, was upregulated and detergent 
solubility profiling indicated that Gpx3 associated with ECM proteins. Immunofluorescence 
analysis showed that Gpx3 was expressed by bronchial epithelial cells and localized to the 
basement membrane in normal mouse lung. In response to bleomycin, Gpx3 was additionally 
found expressed in interstitial fibroblasts and in association with collagen I in the interstitial 
fibrotic ECM. In agreement, we found that phBECs und phLFs express GPX3 in culture. 
While previous studies have shown expression of GPX3 by bronchial epithelial cells and 
presence in the ELF (Avissar et al., 1996, Comhair et al., 2001) as well as localization to the 
basement membrane (Olson et al., 2010, Burk et al., 2011), expression by fibroblasts and 
association to interstitial collagen in the lung has not been reported before. In addition, 
presence of Gpx3 in the lung has been largely attributed to serum Gpx3 supplied by the 
kidneys (Olson et al., 2010, Burk et al., 2011, Yamada et al., 2012). Our study highlights that 
GPX3 is expressed and secreted by mouse and human lung structural cells under 
physiological and pathological conditions and suggests that locally expressed and secreted 
GPX3 significantly contributes to extracellular lung GPX3. 
As to human ILD samples, BALF of some patients contained high levels of GPX3, in 
particular patients with HP and sarcoidosis, i.e. ILDs with an inflammatory component. In 
addition, GPX3 protein was upregulated in lung homogenates from IPF patients. This lead us 
to investigate whether GPX3 expression in phBECs and phLFs was regulated by 
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proinflammatory or profibrotic stimuli, or by the oxidative stress inducer menadione. 
Unexpectedly, we found that GPX3 expression and secretion was consistently downregulated 
by TNF-α in both cell types. Regulation by TGF-β1 and menadione was cell-type-specific: In 
phBECs, TGF-β1 moderately upregulated GPX3 while menadione had no effect. In phLFs, 
also TGF-β1 downregulated GPX3, while menadione increased GPX3 expression and 
secretion.  
In conclusion, the antioxidant enzyme GPX3 is expressed by bronchial epithelial cells and 
secreted in active form into the ELF. GPX3 is upregulated in the  mouse model of bleomycin-
induced lung fibrosis and localizes to lung ELF and the ECM. While only some HP and 
sarcoidosis patients, but not IPF patients, showed high levels of GPX3 in BALF, we found 
significant upregulation of GPX3 in total tissue homogenates from IPF patients. Importantly, 
we could show colocalization of GPX3 with collagen I in the interstitial fibrotic ECM, 
suggesting that GPX3 may protect collagen I in this compartment from oxidative damage. 
4.2 FK506-binding protein 10 is upregulated in ILD including IPF and localizes 
to lung fibroblasts (Paper II) (Staab-Weijnitz et al., 2015) 
Increased abundance and stiffness of the extracellular matrix (ECM), in particular collagens, 
is a general characteristic of organ fibrosis, including fibrosis of the lung. FKBP10 is a 
collagen chaperone, mutations of which are described to lead to reduced collagen crosslinking 
and ECM stiffness, e.g. in osteogenesis imperfecta. Here we hypothesized that FKBP10 is 
upregulated in lung fibrosis. 
To this end, we initially analyzed Fkbp10 expression in the mouse model of bleomycin-
induced lung fibrosis using qRT-PCR, Western Blot, and immunofluorescence. We found that 
Fkbp10 expression was increased up to five-fold 14 days after bleomycin instillation, the time 
point where fibrosis peaks in our model (Schiller et al., 2015, Staab-Weijnitz et al., 2015, 
Fernandez et al., 2016), both at transcript and protein level. Immunofluorescence analysis 
using the myofibroblast marker α-smooth muscle actin (α-SMA) and the alveolar epithelial 
cell markers podoplanin (T1α), or thyroid transcription factor 1 (TTF1) demonstrated 
expression in interstitial (myo-)fibroblasts, but not in alveolar type I and type II epithelial 
cells, respectively (Staab-Weijnitz et al., 2015). 
Then, we analysed microarray data from 99 IPF patients and 43 control subjects derived from 
samples of the Lung Tissue Research Consortium (LTRC), a resource program of the U.S. 
National Heart Lung and Blood Institute. FKBP10 was strongly and highly significantly 
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upregulated in IPF lung samples. Western Blot Analysis of lung homogenates derived from 6 
IPF patients and 5 control subjects from our in-house CPC BioArchive confirmed 
upregulation of FKBP10 in an independent cohort. Similar to fibrotic mouse lung, FKBP10 
was found expressed in interstitial (myo-)fibroblasts and not in alveolar epithelial cells in IPF 
lung tissue. In addition, we found FKBP10 localized in CD68
+
 macrophages (Staab-Weijnitz 
et al., 2015). We also compared baseline expression in phLFs with baseline expression levels 
and, for some, also the TGF-β-induced fold change of FKBP10 induction in the following cell 
types and lines: PhBECs, differentiated at the air-liquid interface (Schamberger et al., 2015), 
the human bronchial epithelial cell line 16-HBE, the human alveolar epithelial cell line A549, 
primary human alveolar type II (phAT2) cells (courtesy of Dr. Kathrin Mutze and Prof. Dr. 
Dr. Melanie Königshoff, CPC Munich), and the murine alveolar macrophage line MH-S. In 
agreement with our results from our immunoflourescence-based colocalization studies, phLFs 
had by far the highest baseline expression levels and also showed the greatest ability to 
upregulate FKBP10 expression (about 3-fold) in response to TGF-β1 (see Figure 4, 
unpublished data). 
 
Figure 4: Baseline expression of FKBP10 and induction by TGF-β1 in selected cell types. Left-hand panel: 
Baseline expression of FKBP10 normalized to expression of hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) demonstrates highest expression levels in primary human lung fibroblasts (phLFs). Right-hand panel: In 
response to 2 ng/ml TGF-β1, phLFs show the greatest ability to further induce FKBP10 expression. 
 
Finally, a recent proteomic analysis confirmed upregulation of FKBP10 in end-stage ILD, 
including IPF, but also non-IPF ILD such as HP, suggesting that FKBP10 overexpression is a 
general characteristic of lung fibrosis, irrespective of cause. In contrast, FKBP10 was not 
increased in fibrotic skin samples from scleroderma patients (Schiller et al., in revision). In 
collaboration with Dr. Lange-Sperandio (Hospital of the Ludwig-Maximilian University of 
19 
Munich, Germany), we have observed that Fkbp10 is induced in the unilateral ureteral 
obstruction (UUO) mouse model for kidney fibrosis (unpublished data, not shown). Taken 
together, these findings suggest that FKBP10 overexpression may be specific for fibrosis of 
internal organs.  
4.3 Primary human lung fibroblasts and human precision-cut lung slices are 
suitable in vitro models for lung fibrosis (Papers II, III, and IV) (Staab-
Weijnitz et al., 2015, Alsafadi et al., 2017, Knüppel et al., 2017)  
Lung fibrosis is a complex process involving infiltration and differentiation of several cell 
types including cells of the immune compartment and, clearly, animal models for lung fibrosis 
are indispensable to study disease pathogenesis in the whole organism. Nevertheless, there is 
no animal model that recapitulates all characteristics of human pulmonary fibrosis (Moore et 
al., 2008, Antoniu et al., 2009). Moreover, it is very well-acknowledged that considerable 
species-species differences exist between human and the most frequently used experimental 
animal, the mouse. Ultimately, this is reflected by the fact, that unfortunately many 
therapeutic approaches which work in mouse models are not effective in patients (Mestas et 
al., 2004, Martignoni et al., 2006). Therefore, human in vitro approaches must be developed 
and applied in the quest for novel drug targets.  
Frequently, lung cell lines are used for in vitro studies of collagen biosynthesis in the context 
of lung fibrosis research. These include fetal fibroblast lines like HLF, MRC5 or the mouse 
lung fibroblast line CCL206 as well as epithelial lung cell lines, as e.g. the adenocarcinoma 
cell line A549 (Hisatomi et al., 2012, Liu et al., 2013, De Langhe et al., 2014, Yang et al., 
2014). These cell lines are easy-to-handle, provide an unlimited supply of comparatively 
homogeneous cell material, and circumvent ethical issues associated with material derived 
from patients. However, it has been shown that fetal fibroblasts differ dramatically in gene 
expression and response to TGF-β1 (Rolfe et al., 2007, Navarro et al., 2009). A549 cells 
produce at best a tenth of the collagen produced by phLFs in our hands, and CCL206 cells, 
even if they have comparable COL1A1 transcript levels, show substantially less collagen 
secretion and do not upregulate collagen secretion in response to TGF-β1 (unpublished 
observations). 
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Figure 5: Primary human lung fibroblasts differentiate to myofibroblasts in response to TGF-β1. 
Treatment of phLFs with 2 ng/ml TGF-β1 results in cell hypertrophy, increased expression of α-smooth muscle 
actin (α-SMA), and generation of stress fibers, all characteristics of the myofibroblast. FKBP10, FK506-binding 
protein, see text. 
 
Therefore, we established an in vitro model of lung fibrosis using phLFs, derived from IPF 
patient explants, healthy donor lungs, or normal histology regions from lung tumor resections. 
We included physiological concentrations (2 ng/ml) of TGF-β1 as central profibrotic cytokine 
which is well-known to induce differentiation to myofibroblasts and collagen gene 
transcription (cf. Figure 5). Another crucial component of the cell culture medium was 2-
phosphoascorbate, a stable form of ascorbate, which is an essential cofactor of all collagen 
lysyl and prolyl hydroxylases, but often omitted in in vitro studies of collagen biosynthesis 
(Hata et al., 1989, Chen et al., 2009). Under these conditions, independent of cell origin, 
phLF consistently and reproducibly secreted high and easily detectable levels of secreted 
collagen, including total collagen, collagen I, and collagen III (Staab-Weijnitz et al., 2015, 
Knüppel et al., 2017). Notably, in prolonged fibroblast culture, we could collect enough 
collagen from cell culture supernatant to allow for fractionation, purification and analysis of 
the different collagen types via polyacrylamide gel electrophoresis, in gel digestion, and 
MS/MS analysis. Furthermore, by electron microscopy, we were able to detect deposited 
collagen fibrils under these conditions (Knüppel et al., 2017), which frequently is limited in in 
vitro systems to study fibrogenesis (Chen et al., 2009). Collectively, this demonstrates that 
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culture of phLFs in presence of 2-phosphoascorbate and TGF-β1 represents a suitable model 
to study collagen biosynthesis, secretion, and deposition in the context of lung fibrogenesis.  
A drawback of human cell culture is certainly the fact that normal tissue architecture and cell 
composition is not maintained. This can be bypassed by tissue culture approaches. Therefore, 
we took advantage of a technology established at the institute which allows for the generation 
of precision-cut lung slices (PCLS) from human lung (Uhl et al., 2015). IPF explant-derived 
PCLS have been used previously to evaluate a potential novel drug for IPF (Mercer et al., 
2016). Here, we reasoned that incubation of PCLS derived from normal histology human lung 
tissue with key profibrotic mediators would result in increased ECM deposition and aberrant 
tissue repair (Alsafadi et al., 2017).   
We chose to use a cocktail of the profibrotic mediators TGF-β1, platelet-derived growth 
factor AB (PDGF-AB), tumor necrosis factor-α (TNF-α), and lysophosphatidic acid (LPA) for 
the following reasons: TGF-β1 is a profibrotic cytokine secreted by macrophages, epithelial 
cells, endothelial cells, and mesenchymal cells, which is well-known to play a central role in 
fibrogenesis of all organs, by recruiting and activating fibroblasts, inducing differentiation to 
myofibroblasts, and increasing ECM production (Agostini et al., 2006, Fernandez et al., 2012, 
Rockey et al., 2015). PDGF is secreted by macrophages, fibroblasts, epithelial cells, and 
endothelial cells upon injury and induces fibroblast proliferation in the lung (Antoniades et 
al., 1990, Bonner, 2004, Agostini et al., 2006, Noskovicova et al., 2015). The 
proinflammatory cytokine TNF-α, secreted by macrophages, lymphocytes, epithelial cells, 
and endothelial cells, is present in fibrotic areas of the lung and has been shown to induce 
further profibrotic cytokine secretion and also fibroblast proliferation (Zhang et al., 1993, 
Agostini et al., 2006). Finally, LPA was added in order to take into account the more recently 
established role of LPA signaling for the aberrant wound healing response in lung fibrosis, 
including induction of epithelial cell apoptosis, recruitment of fibroblasts, and activation of 
latent TGF-β (Tager et al., 2008, Shea et al., 2012).   
PCLS from each patient were treated with this fibrosis cocktail (FC) and vehicle control in 
parallel. Incubation of PCLS with FC did not affect viability of PCLS in the analyzed time 
frame (5 days) relative to vehicle control. We analyzed gene expression of various markers of 
lung remodeling as well as secretion and deposition of collagen I, fibronectin, and tenascin-C 
as representative ECM proteins. In agreement with our hypothesis, gene expression of CTGF, 
SERPINE1, and MMP7, encoding the tissue remodelling factors connective tissue growth 
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factor (CTGF), plasminogen activator inhibitor-1 (PAI1), and matrix metallopeptidase 7 
(MMP7) was upregulated in response to 48h and 120h incubation with FC. The same was true 
for ACTA2 encoding α-smooth muscle actin (α-SMA), a known marker of myofibroblast 
differentiation, and COL1A1, FN1, and TNC, coding for the ECM proteins collagen I (α1 
chain), fibronectin, and tenascin-C, respectively. On the protein level, we observed increases 
of the mesenchymal marker vimentin, of fibronectin, tenascin-C, and collagen I in the 
majority of PCLS, but mostly unchanged levels of α-SMA. These changes were accompanied 
by significant decreases of alveolar epithelial cell markers including surfactant protein C and 
E-cadherin as well as by downregulation of HOPX expression (Alsafadi et al., 2017). As both 
the SPC-positive AT2 cells and the HOPX-positive cell population represent alveolar 
progenitor cells (Jain et al., 2015), these results suggest depletion of the alveolar progenitor 
cell pool resulting in deficient epithelial regeneration. 
Collectively, these findings demonstrate that incubation of PCLS with FC induces central 
events in lung fibrogenesis, most importantly increased synthesis and deposition of ECM 
proteins and inhibition of alveolar repair. With most changes occurring already after 48 h of 
treatment, this model clearly has potential to allow for evaluation of putative therapeutics in 
the remaining viability window of 3 days.  
4.4 Downregulation of FKBP10 by RNA interference decreases collagen 
biosynthesis and secretion in primary human lung fibroblasts (Paper II) 
(Staab-Weijnitz et al., 2015) 
Following up on our observation that, in lung fibrosis, FKBP10 was mostly expressed by 
interstitial fibroblasts (see 4.2), we used our phLF-based in vitro model of lung fibrosis (cf. 
3.3 and 4.3) to assess subcellular localization, regulation, and function of FKBP10. 
Subcellular localization of FKBP10 was assessed by immunofluorescent stainings and 
subcellular fractionation, collectively demonstrating association with the endoplasmic 
reticulum, in agreement with previous reports (Patterson et al., 2000, Lietman et al., 2014). 
FKBP10 expression in phLF was upregulated by TGF-β1, but downregulated by two 
mechanistically independent ER stress inducers, tunicamycin and thapsigargin. Finally, the 
function of FKBP10 was analyzed in phLF by siRNA-mediated loss-of-function-experiments 
followed by assessment of collagen biosynthesis and secretion as well as other markers of 
lung fibrosis. Knockdown of FKBP10 attenuated expression of pro-fibrotic mediators and 
effectors, including collagens I and V and α-smooth muscle actin, on the transcript and 
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protein level. Importantly, loss of FKBP10 expression significantly suppressed collagen 
secretion by phLF. The effect on collagen secretion was compared with those of the currently 
approved IPF therapeutics and found to be equally strong as submicromolar concentrations of 
nintedanib and even superior to millimolar concentrations of pirfenidone. We therefore 
concluded that FKBP10 may be a novel drug target for IPF (Staab-Weijnitz et al., 2015). 
4.5 Nintedanib is more effective in downregulating collagen biosynthesis and 
secretion than pirfenidone (Paper III) (Knüppel et al., 2017) 
Nintedanib and pirfenidone decelerate lung function decline in IPF, but their underlying 
mechanisms of action are poorly understood. The aim of this study was to elucidate the 
effects of these two IPF drugs on several regulatory levels of collagen biosynthesis and 
maturation in our in vitro model system for lung fibrosis (cf. 3.3 and 4.3), using phLFs 
derived from IPF patients as well as from healthy donor controls. By and large, effects of both 
drugs were similar on IPF and control phLFs, thus independent of cell origin. We found that 
both drugs acted on important regulatory levels in collagen synthesis and processing. Overall, 
nintedanib was more effective in downregulating profibrotic gene expression and collagen 
secretion: For instance, nintedanib consistently downregulated transcript and protein levels of 
basal and TGF-β1-induced collagen I and III in IPF phLF, while pirfenidone only marginally 
reduced COL1A1 and COL3A1 transcripts, effects which did not translate to the protein level. 
In addition, only nintedanib decreased expression of FKBP10 and fibronectin, another ECM 
protein. Further highlighting the superior efficacy of nintedanib in this system, a 
concentration of 0.5 to 1.0 mM pirfenidone, i.e. exceeding the effective concentration of 
nintedanib at least 500 times, was necessary to achieve the described minor effects on 
collagen transcript levels. Notably, serum levels of pirfenidone during standard therapy of IPF 
patients (three daily doses of 801 mg pirfenidone) do not exceed 100 μM (Wollin et al., 
2015), a concentration at which we did not observe any effect on phLF gene expression. 
4.6 Both nintedanib and pirfenidone inhibit collagen fibril assembly (Paper III) 
(Knüppel et al., 2017) 
Electron microscopy of fibroblast cultures treated with nintedanib or pirfenidone revealed 
fewer, shorter and thinner collagen fibril bundles compared with untreated controls. Thickness 
of collagen fibrils was quantified and found to be significantly smaller for fibrils formed in 
presence of nintedanib or pirfenidone. Expression of collagen V, a minor collagen important 
for initiation of extracellular fibrillogenesis, was downregulated by both drugs. Finally, both 
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drugs considerably delayed fibril formation of purified collagen I in a dose-dependent 
manner.  
These results put forward the inhibition of extracellular fibril formation as a completely new 
mechanism of action for both drugs and collectively suggest two independent underlying 
mechanisms: First, as type V collagen is a component of collagen type I fibrils, with an 
important role in fibrogenesis and regulation of fiber size regulation (Wenstrup et al., 2004, 
Parra et al., 2006, Vittal et al., 2013), its downregulation by both drugs very likely contributes 
to the phenomenon of fewer and thinner fibrils in the extracellular space of phLFs described 
here. Importantly, collagen V is heavily overexpressed compared in IPF lungs to normal lungs 
(Vittal et al., 2013).  
Second, we could show that both drugs have a direct effect on the entropy-driven auto-
assembly process underlying collagen I fibril formation (Kadler et al., 1996).  We studied this 
process in a direct manner using purified pepsin-digested collagen I (Ishikawa et al., 2014) 
and found that low micromolar concentrations of both drugs inhibited collagen I fibril 
formation with comparable efficiencies in a dose-dependent manner. The exact molecular 
mechanisms remain obscure, but it can be speculated that pirfenidone and nintedanib directly 
bind to collagen triple helices and mask or alter interaction sites due to changes in 
hydrophobicity or charges on the surface of the triple helix. 
Inhibition of fibril assembly has been proposed by others as anti-fibrotic therapeutic strategy 
(Chung et al., 2008), however, without receiving much attention thus far. The discovery that 
both effective IPF therapeutics act on this level provides new leverage to this concept and 
calls for the development of therapeutics that specifically target collagen fibril formation.  
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5 CONCLUSIONS AND OUTLOOK 
In conclusion, the presented data within this habilitation thesis propose several novel concepts 
for pathogenesis and treatment strategies of IPF. First, GPX3 is secreted by lung structural 
cells and associates with the ECM, including the basal membrane and collagen I in the 
interstitial fibrotic matrix. At this point, the physiological relevance of this observation is 
unclear. Oxidative damage of extracellular collagen may affect collagen turnover in the lung, 
as oxidative post-translational modifications could alter or mask binding sites of proteases. 
Also, ECM signaling pathways may be disrupted by changing binding affinity of collagen 
adhesion receptors as e.g. integrins or discoidin domain receptors. Finally, such oxidative 
post-translational modifications may represent neo-epitopes that trigger autoimmune 
processes, which in turn can aggravate disease progression (Shum et al., 2013). Therefore, it 
is plausible that GPX3 is protective in lung fibrosis, but more research is required to clarify 
this.   
Second, inhibition of the collagen chaperone FKBP10 and/or extracellular collagen fibril 
formation may qualify as novel therapeutic strategies for the treatment of IPF. Considering 
that the ECM appears to play a key role in IPF disease progression (Parker et al., 2014) and 
that collagen constitutes the prevalent ECM component in normal and fibrotic ECM (Decaris 
et al., 2014, Beachley et al., 2015), the primary aim in IPF therapy must be to stop ECM 
deposition. Inhibition of extracellular collagen crosslinking as therapeutic strategy for IPF 
treatment as proposed by Barry-Hamilton et al. (2010) has not shown efficacy in phase II 
studies (http://www.gilead.com/news/press-releases/2016/1/gilead-terminates-phase-2-study-
of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis). Therefore, it can be argued 
that inhibition of collagen deposition must happen at an earlier stage of collagen maturation, 
as e.g. intracellular biosynthesis or fibril formation. Nevertheless, this is an understudied field.  
Luo et al. (2015) have reported collagen prolyl-4-hydroxylase 3, an ER-resident enzyme that 
hydroxylates collagen prolines in the 4-position, as potential target for lung fibrosis. This 
habilitation work highlights two more points of possible intervention, namely inhibition at the 
level of triple helix folding in the ER and inhibition at the level of extracellular fibril 
assembly, which precedes collagen crosslinking. The observation that both IPF therapeutics 
nintedanib and pirfenidone act on fibril formation as well as that nintedanib downregulates 
FKBP10, argues for the concept of directly targeting the collagen biosynthesis/deposition 
pathway. Future work will aim at establishing a screening system to discover new specific 
drugs for these novel targets.   
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Animal models are indispensable for the study of lung fibrogenesis in the whole organism, but 
nevertheless limited in how well they reflect human lung physiology and pathology. In 
addition, recent revisions of legislation and guidelines for animal experimentation compelled 
by the EU Directive 2010/63/EU reflect a growing public opposition to the use of animals in 
medical research, emphasizing the need of the continued development of in vitro methods to 
reduce and replace animal experiments. In this work, we applied in vitro model systems with 
patient-derived cells to study regulation and function of target genes found to be 
overexpressed in disease. Notably, optimization of our fibroblast culture conditions to include 
ascorbate and TGF-β1 allowed for efficient collagen biosynthesis and extracellular 
maturation. Finally, we have established an ex vivo model for IPF, where PCLS from surgical 
resections of normal regions of human lung tissue are incubated with a “fibrosis cocktail” 
including TGF-β1 and other cytokines which efficiently induce a fibrotic phenotype. It is 
anticipated that both models will be useful for evaluating therapeutic approaches for lung 
fibrosis in the future. 
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